Celldex Therapeutics, Inc. (NASDAQ:CLDX) Position Boosted by Eventide Asset Management LLC

Eventide Asset Management LLC raised its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 0.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 3,332,005 shares of the biopharmaceutical company’s stock after acquiring an additional 4,873 shares during the period. Celldex Therapeutics accounts for about 2.0% of Eventide Asset Management LLC’s holdings, making the stock its 9th biggest position. Eventide Asset Management LLC owned 5.02% of Celldex Therapeutics worth $113,255,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in CLDX. Novo Holdings A S purchased a new stake in Celldex Therapeutics in the second quarter valued at approximately $31,458,000. Point72 Asset Management L.P. increased its holdings in shares of Celldex Therapeutics by 51.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after buying an additional 654,194 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Celldex Therapeutics by 19.8% in the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock worth $153,215,000 after buying an additional 604,251 shares during the period. Marshall Wace LLP boosted its holdings in Celldex Therapeutics by 53.3% in the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after acquiring an additional 479,068 shares during the last quarter. Finally, Jennison Associates LLC grew its position in Celldex Therapeutics by 32.0% during the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after acquiring an additional 321,325 shares during the period.

Celldex Therapeutics Trading Up 4.2 %

CLDX opened at $27.89 on Friday. The company’s 50-day moving average price is $29.09 and its 200 day moving average price is $34.55. Celldex Therapeutics, Inc. has a fifty-two week low of $22.93 and a fifty-two week high of $53.18.

Insider Transactions at Celldex Therapeutics

In related news, CEO Anthony S. Marucci bought 11,500 shares of the company’s stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.80% of the company’s stock.

Wall Street Analysts Forecast Growth

CLDX has been the subject of a number of research reports. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. The Goldman Sachs Group began coverage on Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.